As Biotechnology businesses, ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV) and Dare Bioscience Inc. (NASDAQ:DARE), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ContraVir Pharmaceuticals Inc.	N/A	0.00	17.90M	-1.42	0.00
Dare Bioscience Inc.	N/A	0.00	16.74M	-2.92	0.00

Demonstrates ContraVir Pharmaceuticals Inc. and Dare Bioscience Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

	Net Margins	Return on Equity	Return on Assets
ContraVir Pharmaceuticals Inc.	0.00%	0%	-162%
Dare Bioscience Inc.	0.00%	-180.3%	-166.4%

Volatility & Risk

ContraVir Pharmaceuticals Inc. has a 1.49 beta, while its volatility is 49.00% which is more volatile than Standard & Poor’s 500. Dare Bioscience Inc. on the other hand, has 2.25 beta which makes it 125.00% more volatile compared to Standard & Poor’s 500.

Liquidity

ContraVir Pharmaceuticals Inc.’s Current Ratio is 1.6 while its Quick Ratio is 1.6. On the competitive side is, Dare Bioscience Inc. which has a 8.5 Current Ratio and a 8.5 Quick Ratio. Dare Bioscience Inc. is better positioned to pay off short and long-term obligations compared to ContraVir Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both ContraVir Pharmaceuticals Inc. and Dare Bioscience Inc. are owned by institutional investors at 4.9% and 11.4% respectively. Insiders owned 4.17% of ContraVir Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 23.7% of Dare Bioscience Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ContraVir Pharmaceuticals Inc.	7.04%	-22.48%	-44.21%	-65.67%	-87.89%	-14.79%
Dare Bioscience Inc.	5.95%	8.86%	1.14%	-13.59%	-29.37%	25.26%

For the past year ContraVir Pharmaceuticals Inc. had bearish trend while Dare Bioscience Inc. had bullish trend.

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.